Panelists discuss how patient characteristics significantly impact antibody-drug conjugate (ADC) therapy selection, with key factors including the presence and location of brain metastases (due to blood-brain barrier penetration), organ function and comorbidities affecting toxicity risks, and prior treatment history that may influence both efficacy and safety. Treatment decisions require careful individualization.
Pharmacists are crucial in Elevidys administration, ensuring accurate dosing, coordinating treatment timing, and managing adverse effects to optimize patient outcomes.
Panelists discuss how emerging antibody-drug conjugates (ADCs) in metastatic breast cancer (mBC) treatment demonstrate innovation through optimized drug-to-antibody ratios, novel payloads, and targeted approaches to different breast cancer subtypes. Key trials explore combinations with established therapies and potential for improved tolerability profiles. Additional notable studies include comparative effectiveness research between approved ADCs and investigation of biomarker-driven patient selection strategies to maximize therapeutic benefit while minimizing adverse effects.
Panelists discuss how health care professionals recommend lifestyle modifications, dietary changes, and OTC products to manage menopause symptoms, focusing on exercise, nutrition, stress reduction, and targeted supplements to support overall well-being during this transitional period.
Panelists discuss how health care professionals develop personalized menopause management strategies by comprehensively assessing individual medical history, symptom profiles, lifestyle factors, and potential risks. Through transparent, collaborative counseling, they guide patients in making informed decisions about pharmacologic therapies, prioritizing personalized care and holistic well-being.
Patients may have concerns about the boxed warning and other potential adverse effects associated with topical ruxolitinib for atopic dermatitis and vitiligo.
Wafa Samara, PharmD, vice president and chief pharmacy officer at City of Hope, highlights the vital role of oncology pharmacists at City of Hope in improving patient outcomes, conducting and leading research, and working as integral members of the multidisciplinary care team.
Long-acting injectables offer a promising approach to schizophrenia treatment, but their effective use requires careful management and patient education.
AI can streamline biosimilar adoption by simplifying prescribing decisions and reducing costs.
Amir Ali, PharmD, BCOP, discusses his experience as an oncology pharmacist in both direct and indirect patient care at the University of Southern California (USC) Norris Comprehensive Cancer Center.
Michael McGuire, PharmD, highlights the importance of early intervention in hospital settings, leveraging manufacturer programs, and navigating complex dosing regimens.
Elevidys offers significantly higher dystrophin production than existing Duchenne muscular dystrophy treatments but requires intensive monitoring for adverse events.
Panelists discuss how when making antibody-drug conjugate (ADC) treatment decisions for patients with metastatic breast cancer (mBC), pharmacists primarily consider patient-specific factors such as biomarker status, prior therapies, disease burden, and comorbidities. ADCs are typically introduced after standard first-line treatments show inadequacy or in specific molecular subtypes that demonstrate strong responses to targeted therapy.
Panelists discuss how menopause care requires a holistic, patient-centered approach involving thorough medical assessment, interdisciplinary collaboration, personalized risk management, and comprehensive support addressing physical, psychological, and preventive health care needs.
Panelists highlight how effective communication requires health care professionals to demonstrate empathy, actively listen, provide evidence-based information, and develop individualized treatment strategies that address the physical and psychological aspects of the menopausal transition.
Panelists discuss how antibody-drug conjugates (ADCs) for breast cancer (BC) differ in their safety profiles, with trastuzumab deruxtecan (T-DXd) having notable interstitial lung disease risk, sacituzumab govitecan (SG) associated with neutropenia/diarrhea, and datopotamab deruxtecan (Dato-DXd) showing a relatively favorable safety profile but still requiring monitoring.
Pharmacists have been central to vaccine distribution since the COVID-19 pandemic, and as viruses spread, they must continue urging patients to stay updated on vaccinations to prevent severe illness and reduce hospitalizations.
Obinutuzumab is effective in reducing proteinuria and preserving kidney function in lupus nephritis, with consistent benefits across high-disease activity subgroups.
LAIs offer a variety of benefits, from improved medication adherence and relapse prevention to enhanced quality of life for individuals with schizophrenia.
Tuberculosis is a long-standing global health issue that requires continued public health vigilance to prevent a resurgence of this preventable and curable disease.
Pharmacists are integral to setting patient expectations, monitoring liver health, and ensuring adherence to long-term follow-up for optimal outcomes with etranacogene dezaparvovec.
Panelists discuss how comprehensive educational resources are essential for empowering patients with TD to better understand their condition, actively participate in their treatment decisions, and achieve optimal outcomes through improved self-management and adherence.
Panelists discuss how pharmacists employ multiple strategies to support medication adherence in older adults with TD, including simplifying dosing regimens, utilizing medication synchronization programs, providing medication packaging solutions, conducting regular follow-up calls, and collaborating closely with prescribers and care teams to develop and adjust personalized treatment plans that address individual patient needs and barriers to care.
If approved, gepotidacin (GSK) will be a new oral agent added to the treatment paradigm for urinary tract infections (UTIs).
Panelists discuss how health care professionals recommend physician consultations for persistent symptoms, complex medical histories, diagnostic uncertainties, specialist needs, urgent conditions, preventive care, medication management, and comprehensive health assessments.
Panelists explain how health care professionals evaluate menopause symptoms using validated questionnaires, symptom tracking, clinical interviews, hormonal tests, and patient-reported outcome measures to comprehensively assess severity and quality-of-life impact.
Pharmacists must consider drug Interactions, allergies, and comorbidities when treating patients with urinary tract infections (UTIs).
Panelists discuss how HER2 testing optimization requires multisite sampling and quantitative assessment methods to account for intratumoral heterogeneity. Beyond HER2, biomarkers such as PI3K mutations, hormone receptor status, and tumor mutational burden can guide therapy selection for metastatic breast cancer (mBC), enabling more personalized treatment approaches.
Panelists discuss how antibody-drug conjugates (ADCs) show varying efficacy and adverse event (AE) profiles based on their payload potency, linker stability, and drug-to-antibody ratio. Cleavable linkers enable targeted drug release but may increase toxicity, while noncleavable designs offer better stability. Payload selection impacts both therapeutic index and AEs, with more potent warheads requiring careful optimization of targeting and release kinetics.
